BELITE BIO INC - AMERICAN DEPOSITARY SHARES

Belite Bio to Host Conference Call on August 11, 2022 to Discuss First Half 2022 Financial Results

01 8 2022 16:10:00 提供 Nasdaq GlobeNewswire

Belite Bio Submits Investigational New Drug (IND) Application to FDA for Approval to Proceed with LBS-008 Phase 3 Clinical Trial for the Treatment of Stargardt Disease

19 7 2022 16:05:33 提供 Nasdaq GlobeNewswire

Belite Bio Announces Partial Exercise of Over-Allotment Option in Initial Public Offering

12 5 2022 16:30:00 提供 Nasdaq GlobeNewswire

Belite Bio Presented Interim Results of LBS-008 Phase 1b/2 Study in Adolescent STGD1 at ARVO Annual Meeting 2022

05 5 2022 08:00:02 提供 Nasdaq GlobeNewswire

Belite Bio Announces Closing of $36 Million Initial Public Offering

03 5 2022 16:30:00 提供 Nasdaq GlobeNewswire

Belite Bio Receives FDA Fast Track Designation For LBS-008

03 5 2022 06:50:00 提供 Nasdaq GlobeNewswire